Organization
CARsgen Therapeutics
8 clinical trials
2 abstracts
Clinical trial
Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR BCMA T Cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
An Open, Multicenter, Phase Ib/II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection in Patients With Advanced Gastric/ Gastroesophageal Junction Adenocarcinoma and Pancreatic CancerStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase 1/2 Open Label Study to Evaluate the Safety and Efficacy of CT071, an Autologous Anti-GPRC5D CAR T, in Relapsed/Refractory Multiple Myeloma (RRMM) or Relapsed/Refractory Primary Plasma Cell Leukemia (RRpPCL)Status: Not yet recruiting, Estimated PCD: 2027-06-15
Clinical trial
Open-label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects With Advanced Gastric, Pancreatic, or Other Specified Digestive System CancersStatus: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
An Open, Two-stage, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AB011 Injection in Patients With CLDN18.2-positive Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-07-27
Clinical trial
Open Label, Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Fully Human Anti-BCMA Chimeric Antibody Receptor Autologous T Cell （CAR T）in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
An Open-label, Single-arm, Multicenter, Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of CT041 Autologous CAR T Cell Injection After Adjuvant Chemotherapy in Subjects With Pancreatic CancerStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
An Open, Multi-center Phase Ⅰ/II Clinical Study to Evaluate the Safety and Efficacy of CT032 Humanized CD19 Autologous Car T Cell Injection in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell LymphomaStatus: Completed, Estimated PCD: 2021-01-20
Abstract
Claudin18.2-targeted chimeric antigen receptor T cell-therapy for patients with gastrointestinal cancers: Final results of CT041-CG4006 phase 1 trial.Org: Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China, Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Beijing Cancer Hospital, Beijing, China, Department of Gastrointestinal Oncology, Beijing Cancer Hospital, Beijing, China, Peking University Cancer Hospital and Institute, Beijing, China,
Abstract
Phase I trial of chimeric anti-GPC3 scFv-CD3ε engineered T cells (CT0180) in patients with advanced hepatocellular carcinoma.Org: CARsgen Therapeutics Ltd., Co., Shanghai, China, CARsgen Therapeutics, CARsgen Therapeutics, Inc, Houston, TX,